| 摘要 |
<p>1.4;3.6-Dianhydrohexitol nitrates substituted by purine bases, namely, adenyl-desoxy-1.4;3.6-dianhydrohexitol nitrates of the general formula Ia as well as theophyllinyl-desoxy-1.4;3.6-dianhydrohexitol nitrates of the general formula Ib, < IMG > (Ia) (Ib) wherein R1 and R2 are the same or different and, independently of one another signify (a) a hydrogen atom, (b) a straight-chained or branched alkyl group with 1 to 7 Catoms, (c) an .omega.-phenylalkyl group, whereby the alkyl group has 1 to 7 C-atoms and whereby the phenyl ring can be halogen-substituted in the p-position, or wherein (d) R1 signifies one of the residues given under (a) to (c) and R2 an acyl radical or an aliphatic, possibly methyl-substituted monocarboxylic acid with 2 to 7 C-atoms, or wherein (e) R1 and R2, together with the nitrogen atom to which they are bound, represent the residue of a cyclic, non-aromatic, secondary amine possibly containing a further hetero atom, as well as their physiologically acceptable acid-addition salts. Process for the preparation of said compounds and pharmaceutical compositions containing said compounds. The compounds can increase coronary flow-through, are spasmalytic, and lower blood pressure.</p> |
